Love B B, Biller J, Gent M
Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.
Drug Saf. 1998 Aug;19(2):89-98. doi: 10.2165/00002018-199819020-00002.
Ticlopidine is an antiplatelet agent that is used to reduce the occurrence of atherothrombotic arterial events. There have been major multicentre placebo-controlled trials evaluating its use in stroke, peripheral arterial disease and unstable angina. In rare cases, adverse haematological effects have been seen with ticlopidine. Ticlopidine has been associated with neutropenia in some of the major trials and in subsequent case reports it has been associated with aplastic anaemia, thrombocytopenia and thrombotic thrombocytopenic purpura, which have been fatal in some instances. Ticlopidine should be used only in patients with an established indication for its use. Patients should be educated about the potential adverse effects and complications associated with ticlopidine, including possible death. Finally, there should be careful attention to haematological monitoring to screen for and promptly detect any adverse effects.
噻氯匹定是一种抗血小板药物，用于减少动脉粥样硬化血栓形成性动脉事件的发生。已经有主要的多中心安慰剂对照试验评估了其在中风、外周动脉疾病和不稳定型心绞痛中的应用。在罕见情况下，使用噻氯匹定可见不良血液学效应。在一些主要试验中，噻氯匹定与中性粒细胞减少有关，在随后的病例报告中，它与再生障碍性贫血、血小板减少和血栓性血小板减少性紫癜有关，在某些情况下是致命的。噻氯匹定仅应用于有明确适应证的患者。应告知患者与噻氯匹定相关的潜在不良反应和并发症，包括可能的死亡。最后，应密切关注血液学监测，以筛查并及时发现任何不良反应。
